Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-analysis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Backgrounds/Aims: Despite advances in antiviral therapy for hepatitis C virus (HCV) infection, hepatocellular carcinoma (HCC) still develops even after sustained viral response (SVR) in patients with advanced liver fibrosis or cirrhosis. This meta-analysis investigated the predictive performance of vibration-controlled transient elastography (VCTE) and fibrosis 4-index (FIB-4) for the development of HCC after SVR. Methods: We searched PubMed, MEDLINE, EMBASE, and the Cochrane Library for studies examining the predictive performance of these tests in adult patients with HCV. Two authors independently screened the studies’ methodological quality and extracted data. Pooled estimates of sensitivity, specificity, and area under the curve (AUC) were calculated for HCC development using random-effects bivariate logit normal and linear-mixed effect models. Results: We included 27 studies (169,911 patients). Meta-analysis of HCC after SVR was possible in nine VCTE and 15 FIB-4 studies. Regarding the prediction of HCC development after SVR, the pooled AUCs of pre-treatment VCTE >9.2–13 kPa and FIB-4 >3.25 were 0.79 and 0.73, respectively. VCTE >8.4–11 kPa and FIB-4 >3.25 measured after SVR maintained good predictive performance, albeit slightly reduced (pooled AUCs: 0.77 and 0.70, respectively). The identified optimal cut-off value for HCC development after SVR was 12.6 kPa for pre-treatment VCTE. That of VCTE measured after the SVR was 11.2 kPa. Conclusions: VCTE and FIB-4 showed acceptable predictive performance for HCC development in patients with HCV who achieved SVR, underscoring their utility in clinical practice for guiding surveillance strategies. Future studies are needed to validate these findings prospectively and validate their clinical impact.
Abstract
Backgrounds/Aims: Despite advances in antiviral therapy for hepatitis C virus (HCV) infection, hepatocellular carcinoma (HCC) still develops even after sustained viral response (SVR) in patients with advanced liver fibrosis or cirrhosis. This meta-analysis investigated the predictive performance of vibration-controlled transient elastography (VCTE) and fibrosis 4-index (FIB-4) for the development of HCC after SVR. Methods: We searched PubMed, MEDLINE, EMBASE, and the Cochrane Library for studies examining the predictive performance of these tests in adult patients with HCV. Two authors independently screened the studies’ methodological quality and extracted data. Pooled estimates of sensitivity, specificity, and area under the curve (AUC) were calculated for HCC development using random-effects bivariate logit normal and linear-mixed effect models. Results: We included 27 studies (169,911 patients). Meta-analysis of HCC after SVR was possible in nine VCTE and 15 FIB-4 studies. Regarding the prediction of HCC development after SVR, the pooled AUCs of pre-treatment VCTE >9.2–13 kPa and FIB-4 >3.25 were 0.79 and 0.73, respectively. VCTE >8.4–11 kPa and FIB-4 >3.25 measured after SVR maintained good predictive performance, albeit slightly reduced (pooled AUCs: 0.77 and 0.70, respectively). The identified optimal cut-off value for HCC development after SVR was 12.6 kPa for pre-treatment VCTE. That of VCTE measured after the SVR was 11.2 kPa. Conclusions: VCTE and FIB-4 showed acceptable predictive performance for HCC development in patients with HCV who achieved SVR, underscoring their utility in clinical practice for guiding surveillance strategies. Future studies are needed to validate these findings prospectively and validate their clinical impact.
참고문헌 (45)
- Lee JH, "Yoon et al. Hepatocellular Carcinoma in Korea : an Analysis of the 2015 Korean Nationwide Cancer Registry", J Liver Cancer, 22, pp.207~ (2022)
- Karim MA, "Clinical characteristics and outcomes of nonalcoholic fatty liver disease-associated hepatocellular carcinoma in the United States", Clin Gastroenterol Hepatol, 21, pp.670~680 (2023)
- De Mitri MS, "HCV-associated liver cancer without cirrhosis", Lancet, 345, pp.413~415 (1995)
- Hajarizadeh B, "Epidemiology and natural history of HCV infection", Nat Rev Gastroenterol Hepatol, 10, pp.553~562 (2013)
- McGlynn KA, "Epidemiology of hepatocellular carcinoma", Hepatology, 73(Suppl 1), pp.4~13 (2021)
- Yu ML, "A sustained virological response to interferon or interferon", ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C : a nationwide, multicentre study in Taiwan, 2006, pp.11, 985~994
- Lee HW, "Costeffectiveness of chronic hepatitis C screening and treatment", Clin Mol Hepatol, 28, pp.164~173 (2022)
- Pons M, "Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals", J Hepatol, 72, pp.472~480 (2020)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C : Final update of the series☆", J Hepatol, 73, pp.1170~1218 (2020)
- Bhattacharya D, "Lo Re V; AASLD-IDSA HCV Guidance Panel", Hepatitis C guidance (2023)[DOI]
- Shiratori Y, "Antiviral therapy for cirrhotic hepatitis C : association with reduced hepatocellular carcinoma development and improved survival", Ann Intern Med, 142, pp.105~114 (2005)
- D’Ambrosio R, "The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response", J Hepatol, 59, pp.251~256 (2013)
- Whiting PF, "QUADAS-2 : a revised tool for the quality assessment of diagnostic accuracy studies", Ann Intern Med, 155, pp.529~536 (2011)
- Shim SR, "Meta-analysis of diagnostic test accuracy studies with multiple thresholds for data integration", Epidemiol Health, 44, pp.e2022083~ (2022)
- Kramer JR, "Longitudinal associations of risk factors and hepatocellular carcinoma in patients with cured hepatitis C virus infection", Am J Gastroenterol, 117, pp.1834~1844 (2022)
- Kuo YH, "Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus", Kaohsiung J Med Sci, 38, pp.268~276 (2022)
- Liu YC, "Comparing predictability of non-invasive tools for hepatocellular carcinoma in treated chronic hepatitis C patients", Dig Dis Sci, 68, pp.323~332 (2023)
- Morisco F, "Risk factors for liver decompensation and HCC in HCV-cirrhotic patients after DAAs : a multicenter prospective study", Cancers(Basel), 13, pp.3810~ (2021)
- Nakai M, "Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication", Sci Rep, 12, pp.1449~ (2022)
- Rinaldi L, "Role of liver stiffness measurement in predicting HCC occurrence in direct-acting antivirals setting : a reallife experience", Dig Dis Sci, 64, pp.3013~3019 (2019)
- Wang JH, "Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy", Liver Int, 36, pp.1793~1799 (2016)
- Ogawa E, "Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination", Aliment Pharmacol Ther, 52, pp.866~876 (2020)
- Sohn W, "Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007-2021 : a nationwide, multicentre, retrospective cohort study", EClinicalMedicine, 73, pp.102671~ (2024)
- Ciancio A, "Who should not be surveilled for HCC development after successful therapy with DAAS in advanced chronic hepatitis C? Results of a long-term prospective study", Biomedicines, 11, pp.166~ (2023)
- Zou Y, "Repeated measurement of FIB-4 to predict long-term risk of HCC development up to 10 years after SVR", J Hepatocell Carcinoma, 9, pp.1433~1443 (2022)
- Ideno N, "Fib-4 index predicts prognosis after achievement of sustained virologic response following direct-acting antiviral treatment in patients with hepatitis C virus infection", Eur J Gastroenterol Hepatol, 35, pp.219~226 (2023)
- Kumada T, "Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus", J Viral Hepat, 29, pp.919~929 (2022)
- Azzi J, "Prediction of hepatocellular carcinoma in hepatitis C patients with advanced fibrosis after sustained virologic response", Clin Res Hepatol Gastroenterol, 46, pp.101923~ (2022)
- Caviglia GP, "Long-term hepatocellular carcinoma development and predictive ability of non-invasive scoring systems in patients with HCV-related cirrhosis treated with direct-acting antivirals", Cancers(Basel), 14, pp.828~ (2022)
- Tada T, "A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response", JGH Open, 6, pp.20~28 (2022)
- Ampuero J, "A 2-step strategy combining FIB-4 with transient elastography and ultrasound predicted liver cancer after HCV cure", Am J Gastroenterol, 117, pp.138~146 (2022)
- Tahata Y, "Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of directacting anti-virals", Aliment Pharmacol Ther, 54, pp.1340~1349 (2021)
- Kumada T, "Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication", Eur J Gastroenterol Hepatol, 33(1S Suppl 1), pp.e513~e521 (2021)
- Matsumae T, "Thrombospondin-2 as a predictive biomarker for hepatocellular carcinoma after hepatitis C virus elimination by directacting antiviral", Cancers(Basel), 15, pp.463~ (2023)
- Myojin Y, "Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination", Aliment Pharmacol Ther, 55, pp.422~433 (2022)
- Ide T, "Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development : a prospective, multicenter study", Hepatol Int, 13, pp.293~301 (2019)
- Nagaoki Y, "Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients", Hepatol Res, 50, pp.1222~1233 (2020)
- Hiraoka A, "Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after direct acting antivirals : multicenter analysis", J Gastroenterol Hepatol, 34, pp.436~441 (2019)
- Ioannou GN, "Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores", Gastroenterology, 157, pp.1264~1278 (2019)
- Tamaki N, "Change in fibrosis 4 index as predictor of high risk of incident hepatocellular carcinoma after eradication of hepatitis C virus", Clin Infect Dis, 73, pp.e3349~e3354 (2021)
- Broquetas T, "Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease", Liver Int, 41, pp.2733~2746 (2021)
- Tatler AL, "Recent advances in the non-invasive assessment of fibrosis using biomarkers", Curr Opin Pharmacol, 49, pp.110~115 (2019)
- Graupera I, "Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population", Clin Gastroenterol Hepatol, 20, pp.2567~2576 (2022)
- Sagir A, "Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage", Hepatology, 47, pp.592~595 (2008)
- Arena U, "Acute viral hepatitis increases liver stiffness values measured by transient elastography", Hepatology, 47, pp.380~384 (2008)